Alkem Laboratories — 360° view

Alkem Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹4,552 crore and net profit of ₹667 crore for the September 2026 quarter.

Alkem Laboratories (NSE: ALKEM) closed at ₹5,185.00 on 20 Nov 2026, down 9.0% over the past year. Its market capitalisation is ₹61,994 crore and it trades at 28.7 times earnings.

Share price
₹5,185.00 (20 Nov 2026)
Market cap
₹61,994 Cr (20 Nov 2026)
P/E
28.67 (20 Nov 2026)
Revenue
₹4,552 Cr (September 2026 quarter)
Net profit
₹667 Cr (September 2026 quarter)
ROCE
21.2% (FY26)
ROE
18.9% (FY26)
Book value
₹1,243 (FY26)
Dividend yield
1.02% (last 12 months to 20 Nov 2026)
52-week high / low
₹5,933.50 / ₹4,811.00 (20 Nov 2026)
1-year return
-9.0% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: ALKEM

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.